Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases

Biomedicine and Pharmacotherapy

Volumn 63, Issue 10, 2009, Pages 762-766

  Mastella, Aline K ^a   Moresco, Rafael N ^a   Bisognin da Silva, Dievan ^a   Becker, Aline M ^a   Duarte, Marta M M F ^b   Giovelli, Letícia L ^a   Huber da Silva, Sandra ^a   Rossato, Luana ^a   Moretto, Maria B ^a   Paz da Silva, José E ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Inflammation; Ischemia; Myocardial infarction; Oxidative stress; Prostate

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISCHEMIA MODIFIED ALBUMIN; TROPONIN I;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 71749120414     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.12.002     Document Type: Article

References (21)

1. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21 (2000) 1502-1513
2. Moresco R.N., Vargas L.C.R., Halla-Júnior R., and Silla L.M.R. Lack of association between cardiac troponin T and D-dimer in the evaluation of myocardial damage. J Clin Lab Anal 19 (2005) 282-284
3. Plebani M., and Zaninotto M. Cardiac markers: present and future. Int J Clin Lab Res 29 (1999) 56-63
4. Sarko J., and Pollack C.V. Cardiac troponins. J Emerg Med 23 (2002) 57-65
5. Aparci M., Kardesoglu E., Ozmen N., Ozcan O., Cebeci B.S., Cingozbay B.Y., et al. Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coron Artery Dis 18 (2007) 367-373
6. Sinha M.K., Roy D., Gaze D.C., Collinson P.O., and Kaski J.C. Role of "ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21 (2004) 29-34
7. Cichota L.C., Moresco R.N., Duarte M.M.M.F., and Paz da Silva J.E. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 22 (2008) 1-5
8. Bar-Or D., Lau E., and Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med 19 (2000) 311-315
9. Lippi G., Filippozzi L., Montagnana M., Salvagno G.L., and Guidi G.C. Diagnostic value of D-dimer measurement in patients referred to the emergency department with suspected myocardial ischemia. J Thromb Thrombolysis 25 (2008) 247-250
10. Packard R.R.S., and Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54 (2008) 24-38
11. Mishra V.C., Allen D.J., Nicolaou C., Sharif H., Hudd C., Karim O.M., et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?. BJU Int 100 (2007) 327-331
12. Nickel J.C. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35 (2007) 109-115
13. Wang L., Yang J.R., Yang L.Y., and Liu Z.T. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses 70 (2008) 1021-1023
14. Valentini J., Grotto D., Paniz C., Roehrs M., Burg G., and Garcia S.C. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 62 (2008) 378-382
15. Aydin A., Arsova-Sarafinovska Z., Sayal A., Eken A., Erdem O., Erten K., et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 39 (2006) 176-179
16. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., and Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 92 (2006) 113-114
17. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
18. Francisco G., Hernández C., and Simó R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 369 (2006) 1-16
19. Sampietro T., Bigazzi F., Dal Pino B., Fusaro S., Greco F., Tuoni M., et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition?. Circulation 105 (2002) 11-14
20. Wadham C., Albanese N., Roberts J., Wang L., Bagley C.J., Gamble J.R., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109 (2004) 2116-2122
21. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidized LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 318 (2004) 680-683